Please login to the form below

Not currently logged in
Email:
Password:

Pfizer promotes Olivier Brandicourt to emerging markets president

Will also head established products business units following David Simmons’ departure

Olivier Brandicourt - PfizerPfizer has promoted president and general manager of the pharma company's primary care business unit, Dr Olivier Brandicourt, to president and general manager of its emerging markets and established products business units.

Taking over his new position on June 1, he replaces the departing David Simmons who is leaving to become chair and CEO of contract research organisation PPD.

Brandicourt's previous experience at Pfizer includes country and regional management roles in Latin America, Europe, Canada, the UK and the US, and he is also a member of the company's executive leadership team.

“Olivier is ideally suited to take on this new role,” said Ian Read, Pfizer's chair and CEO. “He has more than 20 years of global experience in the pharmaceutical industry.

“Olivier is both a physician and proven business leader who understands the many challenges of today's changing industry and healthcare landscape.”

During his time as a practicing physician, Dr Brandicourt specialised in infectious diseases, and spent two years in the Congo.He also spent four years in West and central Africa working in malaria research as part of an eight-year spell with the tropical disease institute in Paris.

Replacing Dr Brandicourt as president and general manager of the pharma company's primary care business is John Young, who is currently regional president of Europe and Canada for Pfizer.

Young has spent 25 years with the firm, holding several senior commercial roles in Australia/New Zealand and in the UK.

“John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business,” said CEO Read.

24th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics